you are absolutely correct Drano
In the end its up to FDA and/or EMA to decide about the design of the study
I hope, we will have a glance at the protocol soon.
In such an unmet need situation they may settle on simple and straight forward trial with much lower number of patients , however more powered trial gives statistically better chance of success.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links